Earnings summaries and quarterly performance for Metsera.
Research analysts covering Metsera.
Recent press releases and 8-K filings for MTSR.
Metsera Amends Merger Agreement with Pfizer, Reaffirms Support
MTSR
M&A
Legal Proceedings
Proxy Vote Outcomes
- Metsera has entered into an amended merger agreement with Pfizer, valuing the company at up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value right (CVR) entitling holders to additional payments of up to $20.65 per share.
- Metsera's Board of Directors unanimously recommends that stockholders approve the amended Pfizer merger agreement, stating that the revised terms offer the best value and certainty of closing for shareholders.
- The Board determined that a competing transaction proposed by Novo Nordisk presented unacceptably high legal and regulatory risks, including potential antitrust concerns from the U.S. Federal Trade Commission.
- The parties anticipate closing the merger promptly following the stockholder meeting scheduled for November 13.
Nov 8, 2025, 2:32 AM
Metsera responds to litigation ruling
MTSR
Legal Proceedings
M&A
- Metsera, Inc. issued a statement on November 5, 2025, in response to a Delaware Court of Chancery ruling concerning litigation filed by Pfizer.
- The court denied Pfizer's request for a temporary restraining order intended to block Metsera's Board of Directors from acting in the best interests of shareholders.
- Metsera expressed gratification with the decision, while Pfizer has indicated it will continue to litigate.
- This litigation is related to Pfizer's proposed acquisition of Metsera and also impacts Novo Nordisk's unsolicited proposal.
Nov 6, 2025, 1:07 AM
Metsera declares Novo Nordisk's amended proposal superior to Pfizer's offer
MTSR
M&A
Takeover Bid
- Metsera's Board of Directors has determined that a revised proposal from Novo Nordisk to acquire Metsera constitutes a "Superior Company Proposal" compared to the existing Pfizer Merger Agreement.
- The Novo Nordisk Amended Proposal values Metsera at up to $86.20 per share, for a total of approximately $10.0 billion, representing an approximate 159% premium to Metsera's closing price as of September 19, 2025.
- This offer includes an upfront cash payment of $62.20 per share and a contingent value right (CVR) of up to $24.00 per share.
- The Novo Nordisk offer is superior to a revised Pfizer proposal, which valued Metsera at up to $70.00 per share (totaling approximately $8.1 billion), consisting of $60.00 per share in cash and a CVR of up to $10.00 per share.
- Metsera has initiated a two-business-day negotiation period with Pfizer, during which Pfizer can propose adjustments to its merger agreement; the Pfizer Merger Agreement remains in effect. The Novo Nordisk Proposal expires at 10:00 a.m. Eastern Time on November 6, 2025.
Nov 4, 2025, 3:47 PM
Metsera Reports Positive Phase 2b Results for MET-097i
MTSR
New Projects/Investments
- Metsera, Inc. announced positive topline data from its Phase 2b VESPER-1 and positive interim data from VESPER-3 trials for MET-097i, an ultra-long acting GLP-1 receptor agonist.
- In the VESPER-1 trial, MET-097i demonstrated a mean placebo-subtracted weight loss of up to 14.1% after 28 weeks.
- MET-097i showed potentially class-leading tolerability in both trials, with a minimal diarrhea signal and a risk difference from placebo of 13% for nausea and 11% for vomiting at the highest evaluated dose in VESPER-3 after 12 weeks.
- Based on these results, Metsera is on track to initiate a global Phase 3 program in late 2025.
Sep 29, 2025, 9:16 PM
Pfizer to Acquire Metsera
MTSR
M&A
Takeover Bid
- Pfizer Inc. will acquire Metsera, Inc. for $47.50 per share in cash at closing, representing an initial enterprise value of approximately $4.9 billion.
- The agreement includes a non-transferable contingent value right (CVR) entitling holders to potential additional payments of up to $22.50 per share in cash, tied to three specific clinical and regulatory milestones.
- The transaction, unanimously approved by the Boards of Directors of both companies, is expected to close in the fourth quarter of 2025.
- This acquisition will add four highly differentiated clinical-stage incretin and amylin programs to Pfizer's pipeline, focusing on obesity and cardiometabolic diseases.
Sep 22, 2025, 11:41 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more